Literature DB >> 22228189

Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.

Anke J Roelofs1, Charlotte A Stewart, Shuting Sun, Katarzyna M Błażewska, Boris A Kashemirov, Charles E McKenna, R Graham G Russell, Michael J Rogers, Mark W Lundy, Frank H Ebetino, Fraser P Coxon.   

Abstract

Bisphosphonates are widely used antiresorptive drugs that bind to calcium. It has become evident that these drugs have differing affinities for bone mineral; however, it is unclear whether such differences affect their distribution on mineral surfaces. In this study, fluorescent conjugates of risedronate, and its lower-affinity analogues deoxy-risedronate and 3-PEHPC, were used to compare the localization of compounds with differing mineral affinities in vivo. Binding to dentine in vitro confirmed differences in mineral binding between compounds, which was influenced predominantly by the characteristics of the parent compound but also by the choice of fluorescent tag. In growing rats, all compounds preferentially bound to forming endocortical as opposed to resorbing periosteal surfaces in cortical bone, 1 day after administration. At resorbing surfaces, lower-affinity compounds showed preferential binding to resorption lacunae, whereas the highest-affinity compound showed more uniform labeling. At forming surfaces, penetration into the mineralizing osteoid was found to inversely correlate with mineral affinity. These differences in distribution at resorbing and forming surfaces were not observed at quiescent surfaces. Lower-affinity compounds also showed a relatively higher degree of labeling of osteocyte lacunar walls and labeled lacunae deeper within cortical bone, indicating increased penetration of the osteocyte canalicular network. Similar differences in mineralizing surface and osteocyte network penetration between high- and low-affinity compounds were evident 7 days after administration, with fluorescent conjugates at forming surfaces buried under a new layer of bone. Fluorescent compounds were incorporated into these areas of newly formed bone, indicating that "recycling" had occurred, albeit at very low levels. Taken together, these findings indicate that the bone mineral affinity of bisphosphonates is likely to influence their distribution within the skeleton.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228189     DOI: 10.1002/jbmr.1543

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  38 in total

1.  On the pharmacological evaluation of bisphosphonates in humans.

Authors:  Serge Cremers; Frank Hal Ebetino; Roger Phipps
Journal:  Bone       Date:  2020-06-27       Impact factor: 4.398

2.  Bone remodeling markers: so easy to measure, so difficult to interpret.

Authors:  E Seeman; T V Nguyen
Journal:  Osteoporos Int       Date:  2015-11-11       Impact factor: 4.507

3.  A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.

Authors:  Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2018-11-02       Impact factor: 5.858

4.  Bisphosphonates: bone mineral affinity affects skeletal distribution.

Authors: 
Journal:  Bonekey Rep       Date:  2012-06-20

5.  Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.

Authors:  Ranya Elsayed; Pheba Abraham; Mohamed E Awad; Zoya Kurago; Balasudha Baladhandayutham; Gary M Whitford; David H Pashley; Charles E McKenna; Mohammed E Elsalanty
Journal:  Bone       Date:  2018-02-09       Impact factor: 4.398

6.  Bisphosphonate uptake in areas of tooth extraction or periapical disease.

Authors:  Simon Cheong; Shuting Sun; Benjamin Kang; Olga Bezouglaia; David Elashoff; Charles E McKenna; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2014-07-12       Impact factor: 1.895

7.  Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea.

Authors:  Woo Seok Kang; Shuting Sun; Kim Nguyen; Boris Kashemirov; Charles E McKenna; S Adam Hacking; Alicia M Quesnel; William F Sewell; Michael J McKenna; David H Jung
Journal:  Otol Neurotol       Date:  2015-07       Impact factor: 2.311

8.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

9.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

10.  Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.

Authors:  Tetsuo Yano; Mei Yamada; Tomoyuki Konda; Makoto Shiozaki; Daisuke Inoue
Journal:  J Bone Miner Metab       Date:  2013-12-20       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.